Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Actinium Pharmaceuticals, Inc. (ATNM)

Actinium NYSE American accepts compliance plan; listing extended to November 27, 2027

Neutral Impact 3 of 5 legal/regulatory Written later

NYSE Regulation accepted Actinium's compliance plan on August 12, 2026, and granted a plan period through November 27, 2027, to regain compliance with NYSE American continued listing standards. The company's common stock will keep trading on NYSE American during the plan period, but the company remains out of compliance with Sections 1003(a)(ii) and (iii) of the Company Guide.

Key points

  • NYSE American notified the company on May 27, 2026, that it was not in compliance with Sections 1003(a)(ii) and (iii) of the Company Guide.
  • The company submitted its compliance plan on June 18, 2026, and NYSE Regulation accepted it in an August 12, 2026 letter.
  • The plan period runs through November 27, 2027, and the stock continues to trade under the symbol ATNM during this period.
  • If the company does not regain compliance or make progress consistent with the plan by the end of the period, NYSE Regulation may initiate delisting proceedings.

The filing

CompanyActinium Pharmaceuticals, Inc. (ATNM)
Form8-K, current report
Filed with the SECAug 14, 2026, 5:00 PM ET
Accession number0001213900-26-090232

Items reported: 3.01 Delisting / Listing Rule Notice7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.